Danaher Corporation $DHR Shares Sold by WealthPLAN Partners LLC

Key Points

• WealthPLAN Partners LLC significantly reduced its stake in Danaher Corporation by 81% during the 2nd quarter, owning only 1,129 shares after selling 4,827 shares.
• Danaher reported a Q2 EPS of $1.80, exceeding analysts' expectations, with quarterly revenue of $5.94 billion, reflecting a 3.4% year-over-year increase.
• The company declared a quarterly dividend of $0.32, with an annualized dividend yield of 0.6%, to be paid on October 31st to stockholders of record.

WealthPLAN Partners LLC cut its stake in Danaher Corporation (NYSE:DHR - Free Report) by 81.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,129 shares of the conglomerate's stock after selling 4,827 shares during the period. WealthPLAN Partners LLC's holdings in Danaher were worth $223,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Hills Bank & Trust Co grew its position in Danaher by 0.3% in the 1st quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate's stock valued at $3,693,000 after buying an additional 53 shares in the last quarter. Worth Financial Advisory Group LLC grew its position in Danaher by 4.6% in the 2nd quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate's stock valued at $236,000 after buying an additional 53 shares in the last quarter. Sageworth Trust Co grew its position in Danaher by 2.3% in the 1st quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate's stock valued at $493,000 after buying an additional 54 shares in the last quarter. 1834 Investment Advisors Co. grew its position in Danaher by 3.3% in the 1st quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate's stock valued at $342,000 after buying an additional 54 shares in the last quarter. Finally, Bruce G. Allen Investments LLC grew its position in Danaher by 13.1% in the 2nd quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate's stock valued at $92,000 after buying an additional 54 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Up 2.3%

Shares of NYSE:DHR opened at $210.86 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The company has a market cap of $150.99 billion, a PE ratio of 44.86, a price-to-earnings-growth ratio of 2.94 and a beta of 0.77. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $279.41. The firm has a 50 day simple moving average of $201.43 and a 200 day simple moving average of $197.23.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating the consensus estimate of $1.64 by $0.16. The business had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm's quarterly revenue was up 3.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher's dividend payout ratio is 27.23%.

Analyst Ratings Changes

DHR has been the subject of a number of research analyst reports. Wells Fargo & Company cut their price target on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a report on Wednesday, July 23rd. Robert W. Baird upped their price target on shares of Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a report on Friday, July 18th. Royal Bank Of Canada set a $241.00 price target on shares of Danaher in a report on Tuesday, September 2nd. Evercore ISI upped their price target on shares of Danaher from $226.00 to $245.00 and gave the company an "outperform" rating in a report on Tuesday, October 7th. Finally, UBS Group cut their price target on shares of Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a report on Wednesday, July 23rd. Seventeen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $244.60.

Insider Activity

In other news, Director Teri List sold 2,778 shares of the stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares of the company's stock, valued at $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 11.10% of the stock is owned by company insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.